# A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients

> **NCT07517250** · — · NOT_YET_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 160 (estimated)

## Conditions studied

- Familial Mediterranean Fever
- Still Disease
- Systemic Juvenile Idiopathic Arthritis
- Adult-Onset Still Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07517250
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-07
- **Primary completion:** 2026-09-21
- **Final completion:** 2026-09-21
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07517250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07517250, "A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07517250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*